Intertek
- Advanced Therapies Europe
- Exhibitor
- Cell Therapy
- Gene Therapy
- Stem Cell
- Tissue Engineering
- Immunotherapy
- Offering a product/service/solution to therapy developers and other parties
- CRO services
){kind=logo}
Our bespoke, purpose-built GLP / GCP / GMP laboratories have supported developers and manufacturers for over 30 years by providing bioanalytical studies and advanced characterisation programs. We have worked on multiple studies involving cell or gene therapies, mRNA, plasmid DNA based products, and other advanced modalities. Our facility has been designed to handle recombinant genomic materials for the purposes of research and compliant testing, including specialist facilities for handling Class I and Class II Biological Agents.
Intertek’s innovative bio/pharmaceutical services are delivered consistently with precision, pace, and passion, enabling you, our customer, to power ahead safely.
Find out more: www.intertek.com/pharmaceutical/biopharmaceuticals/gene-therapy-characterisation
Contact us today: +44 (0)116 296 1620 | pharma.services@intertek.com
Follow us: www.linkedin.com/showcase/intertek-pharma
Address
Academy Place, 1-9 Brook Streetbrentwood Essex
brentwood Essex
CM14 5NQ
United Kingdom
Contact Exhibitor
-
)
Potency testing quantitatively determines the biological activity of a biopharmaceutical, serving as a critical quality attribute essential for quality control, product release and stability studies. -
)
Explore the latest analytical strategies for AAV characterisation and learn how to optimise your viral vector development. -
)
Intertek's cell and gene therapy experts provide analytical development to help you meet regulatory expectations for safety and efficacy of your products. -
)
Join us for a ground-breaking and insightful forum on inhaled and nasal biologics or inhaled vaccine development. -
)
Implementing effective E&L programs for Advanced Therapeutic Medicinal Products (ATMPs) -
)
Strengthening expertise in inhaled drug laboratory solutions. New bioassay and cell culture units will bring additional capabilities for cell-based potency assays.